NEW YORK, Sept. 11, 2020
/PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or
the "Company") today announced the publication of positive results
from a study of antiviral activity of FDA approved drugs in a
peer-reviewed article in the Journal of Virology. The
publication cites that 17 of the 20 FDA-approved drugs studied
inhibit SARS-CoV-2 at non-cytotoxic concentrations.
Mr. Anthony Hayes, CEO of AIkido
stated, "The publication of a peer-reviewed study in a
highly-revered journal represents additional validation of
University of Maryland, Baltimore's
(UMB) antiviral platform. The results clearly articulate the
technology we have optioned from the university, and we are
encouraged by the opportunities we may be able to pursue with the
platform".
In the article, which was co-authored by investigators from the
University of Maryland School of
Medicine, 17 of the 20 FDA approved drugs against SARS-CoV-2
that also inhibit SARS-CoV and MERS-CoV inhibit SARS-CoV-2 at
non-cytotoxic concentrations suggesting these may have
pan-anti-coronaviral activity.
The full article is available at
https://jvi.asm.org/content/early/2020/08/13/JVI.01218-20.
The Company previously executed a Master License Agreement with
UMB for specific antiviral compounds discovered by UMB that seek to
inhibit replication of multiple viruses, including Influenza virus,
SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus. The technology is
covered by two patent applications already on file with the United
States Patent and Trademark Office. The Company previously executed
a Sponsored Research Agreement with UMB to support the development
of the technology.
About AIkido
AIkido was initially formed in 1967 and is a biotechnology
company with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
AIkido:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@AIkido.com
|
|
www.AIkido.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-peer-reviewed-publication-of-positive-results-from-study-of-antiviral-compounds-licensed-from-university-of-maryland-baltimore-301128035.html
SOURCE AIkido Pharma Inc.